Brief: Livsayis™ (Cemdisiran) Approved By The FDA As First And Only Sirna Therapy In Generalized Myasthenia Gravis And Only Treatment With Four-Times-A-Year Subcutaneous Dosing
BRIEF-Livsayis™ (Cemdisiran) Approved By The FDA As First And Only Sirna Therapy In Generalized Myasthenia Gravis And Only Treatment With Four-Times-A-Year Subcutaneous Dosing Nov 18 (Reuters) - Regeneron Pharmaceuticals, Inc. REGN.O:
LIVSAYIS™ (CEMDISIRAN) APPROVED BY THE FDA AS FIRST AND ONLY SIRNA THERAPY IN GENERALIZED MYASTHENIA GRAVIS AND ONLY TREATMENT WITH FOUR-TIMES-A-YEAR SUBCUTANEOUS DOSING
REGENERON PHARMACEUTICALS - LIVSAYIS AVAILABLE ONLY THROUGH LIVSAYIS REMS PROGRAM
Source text: ID:nGNX8NFpFK
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Regeneron Pharmaceuticals
See all newsCorrected: UPDATE 2-US FDA approves Regeneron's drug for generalized myasthenia gravis (November 18)
Refile: US FDA approves Regeneron's drug for generalized myasthenia gravis
Brief: Livsayis™ (Cemdisiran) Approved By The FDA As First And Only Sirna Therapy In Generalized Myasthenia Gravis And Only Treatment With Four-Times-A-Year Subcutaneous Dosing
US FDA approves Sanofi's genetic disorder drug
Brief: Regeneron Pharmaceuticals Said Single Administration Of CIDEB(siRNA) Led To Reductions In Liver Fat Up To 80% That Were Sustained Through 36 Weeks